Some pharmacogenomic DTC tests that aim to assess a person's response to particular medicines may end up available only through a doctor's prescription, says New Scientist's Peter Aldhous. As FDA moves toward regulating the DTC genetic testing industry, the question of whether pharmacogenomic tests in particular should be regulated is "emerging as a flashpoint," Aldhous says.